Skip to content
Contact ViZEN: (401) 578-6165
LinkedInTwitter
ViZEN | Experts in Visual Communication Logo
  • Services
    • Graphic Design & Data Illustration
    • Web Development & Design
    • Regulatory Meeting Preparation
  • About
  • Alliances
  • Contact
average attention span of the internet userchristine2015-07-26T14:11:38+00:00

VĭZEN /ˈvĭ-zhən/Follow

VĭZEN /ˈvĭ-zhən/
Retweet on TwitterVĭZEN /ˈvĭ-zhən/ Retweeted
Alzheon, Inc.@Alzheon·
16 Sep

Sometimes laughter really is the best medicine and we’re hard at work finding a cure. @Sethrogen and @IamLaurenMiller we applaud you and are grateful for your efforts to raise money and #Alzheimer’s awareness to fight this disease. #Alzheon #EndAlz

Reply on Twitter 1173639811095257088Retweet on Twitter 11736398110952570881Like on Twitter 11736398110952570882Twitter 1173639811095257088
Retweet on TwitterVĭZEN /ˈvĭ-zhən/ Retweeted
Alzheon, Inc.@Alzheon·
10 Sep

Working to prevent #Alzheimer’s similar to the way we treat cardiovascular disease. @MartinTolar explains in this interview clip with Andy Asher of @BloomerBoomer50. Watch the full interview here… https://t.co/nfl1jQ7wD2
#endalz #ALZ801 #Alzheon

Reply on Twitter 1171434481242128390Retweet on Twitter 11714344812421283901Like on Twitter 11714344812421283902Twitter 1171434481242128390
Retweet on TwitterVĭZEN /ˈvĭ-zhən/ Retweeted
Alzheon, Inc.@Alzheon·
9 Sep

Our hearts go out to @DrOz, his family, the many patients and their caregivers who are dealing the terrible disease, #Alzheimers. You are not alone.

#EndALZ #Alzheon #ALZ801

Reply on Twitter 1171102753940267009Retweet on Twitter 11711027539402670091Like on Twitter 11711027539402670091Twitter 1171102753940267009
Load More...

Copyright © ViZEN Studios. All Rights Reserved.

LinkedInTwitter
Toggle Sliding Bar Area

RSS FDA Whats New: Drugs

  • Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product November 15, 2019
  • What's New Related to Drugs November 15, 2019
  • Warning Letters 2019 November 15, 2019

RSS REUTERS: Regulatory News

RSS REUTERS: US Healthcare